<SEC-DOCUMENT>0001213900-25-040436.txt : 20250507
<SEC-HEADER>0001213900-25-040436.hdr.sgml : 20250507
<ACCEPTANCE-DATETIME>20250507091516
ACCESSION NUMBER:		0001213900-25-040436
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250507
FILED AS OF DATE:		20250507
DATE AS OF CHANGE:		20250507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inspira Technologies OXY B.H.N. Ltd
		CENTRAL INDEX KEY:			0001837493
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40303
		FILM NUMBER:		25919553

	BUSINESS ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
		BUSINESS PHONE:		972-9-9664488

	MAIL ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0241039-6k_inspira.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Month of May 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-40303</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Inspira Technologies Oxy B.H.N. Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Translation of registrant&rsquo;s name into
English)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2 Ha-Tidhar St.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ra&rsquo;anana 4366504, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9746; Form 20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;Form
40-F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 7, 2025, Inspira Technologies
Oxy B.H.N. Ltd., or the Registrant, issued a press release titled &ldquo;INSPIRA ART100 System Approved by Israel&rsquo;s Largest Healthcare
Provider for Use in Organ Transplant Patients,&rdquo; a copy of which is furnished as Exhibit 99.1 with this report of foreign private
issuer on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first three paragraphs,
the fifth paragraph and the section titled &ldquo;Forward-Looking Statements&rdquo; in the&nbsp;press release are incorporated&nbsp;by
reference into the Registrant&rsquo;s Registration Statements on Form F-3 (Registration Nos.&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390022046430/ea164081-f3_inspiratech.htm">333-266748</A>&nbsp;and&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390025004023/ea0227763-f3_inspira.htm">333-284308</A>)
and Form&nbsp;S-8 (Registration Nos.&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390021044780/ea146415-s8_inspiratech.htm">333-259057</A>&nbsp;and&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390024023044/ea0201791-s8_inspira.htm">333-277980</A>),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on
Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea024103901ex99-1_inspira.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on May 7, 2025, titled &ldquo;INSPIRA ART100 System Approved by Israel&rsquo;s Largest Healthcare Provider for Use in Organ Transplant Patients.&rdquo;</FONT></A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inspira Technologies Oxy B.H.N. Ltd.</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 7, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea024103901ex99-1_inspira.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY INSPIRA TECHNOLOGIES OXY B.H.N. LTD. ON MAY 7, 2025, TITLED "NSPIRA ART100 SYSTEM APPROVED BY ISRAEL'S LARGEST HEALTHCARE PROVIDER FOR USE IN ORGAN TRANSPLANT PATIENTS."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INSPIRA ART100 System Approved by Israel&rsquo;s
Largest Healthcare Provider for Use in Organ Transplant Patients</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RA&rsquo;ANANA, Israel, May 7, 2025</B> -- Inspira&trade; Technologies
OXY B.H.N. Ltd. (NASDAQ: IINN) (&ldquo;Inspira&rdquo; or the &ldquo;Company&rdquo;), a pioneer in innovative life-support and diagnostic technologies,
today announced that the INSPIRA&trade; ART100 has been approved by Israel&rsquo;s largest healthcare provider to undergo a clinical validation
by leading physicians who intend to use the innovative life-support and diagnostic device during organ transplant procedures. As part
of this advancement, Inspira will deploy the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) approved INSPIRA ART100 system at one
of Israel&rsquo;s renowned medical centers affiliated with the largest health care provider.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A team of pioneering physicians at a renowned medical center has requested
to validate the INSPIRA ART100 system for application in highly complex organ transplant procedures. This deployment will allow leading
Israeli transplant specialists to gain hands-on experience with Inspira&rsquo;s innovative technology, specifically exploring its potential
to maintain organ viability through advanced blood oxygenation. The INSPIRA ART100 system may serve a unique role by providing out of
body blood oxygenation to keep the patient alive during the organ transplant procedure as well as for several hours in the recovery room.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This validation process represents a new clinical application for the
innovative INSPIRA ART100 system, offering the Company a unique opportunity to gather valuable insights from leading medical specialists
as they evaluate the system&rsquo;s performance in demanding transplantation environments. The clinical data collected during these procedures
will be strategically used to support the ongoing development program of Inspira&rsquo;s flagship INSPIRA ART500 system designed to oxygenate
a patient&rsquo;s blood and support vital organs during acute respiratory failure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Being approved by Israel&rsquo;s largest and prestigious healthcare
provider showcases the significant interest our technology is garnering from leading medical institutions, including in our local market,
as well as abroad, as previously reported,&rdquo; said Dagi Ben-Noon, Chief Executive Officer of Inspira. &ldquo;We look forward to working
closely with the provider&rsquo;s medical professionals to explore new applications of our technologies.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The INSPIRA ART100 system was granted FDA 510(k) clearance on May 2024,
for cardiopulmonary bypass procedures and in July 2024 received the Israeli AMAR certification for cardiopulmonary bypass and extra-corporeal
membrane oxygenation (ECMO) procedures. The system&rsquo;s proprietary hardware and software platform serves as the foundation for the Company&rsquo;s
flagship INSPIRA ART500 system, which is currently under development and aims to revolutionize respiratory care by providing direct blood
oxygenation without mechanical ventilation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Inspira Technologies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Inspira Technologies is developing innovative respiratory support and diagnostics technologies. The Company&rsquo;s flagship INSPIRA ART500
system aims to revolutionize critical care by enabling patients to remain awake during treatment while stabilizing oxygen levels without
mechanical ventilation. The FDA-cleared INSPIRA ART100 system has received regulatory approvals for Cardiopulmonary Bypass procedures
in the U.S. and for Cardiopulmonary Bypass procedures and Extra Corporeal Membrane Oxygenation in&nbsp;Israel. The Company&rsquo;s HYLA blood
sensor technology is designed to provide continuous, real-time blood monitoring without the need for blood draws. The Company&rsquo;s pipeline
products, including the INSPIRA ART500, HYLA blood sensor, and Single-use patient kit are currently in development and have not yet received
regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information, visit:&nbsp;https://inspira-technologies.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statement Disclaimer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>This press release contains
express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on
the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking
statements when it discusses the collaboration with Israel&rsquo;s largest healthcare provider, the planned evaluation of the INSPIRA
ART100 system in organ transplant procedures, the potential of the Company&rsquo;s technology to address critical needs in advanced pulmonary
care, that the clinical data collected during the procedures will be used to support the ongoing development program of the INSPIRA ART500
system, and the expected benefits and uses of its products. These forward-looking statements and their implications are based solely
on the current expectations of the Company&rsquo;s management and are subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company
undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting
the Company is contained under the heading &ldquo;Risk Factors&rdquo; in the Company&rsquo;s annual report on Form 20-F for the fiscal year ended
December 31, 2024, filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;), which is available on the SEC&rsquo;s website
at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Inspira Technologies &ndash; Media Relations<BR>
Email: info@inspirao2.com<BR>
Phone: +972-9-9664485</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Capital Markets &amp; Investor Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Arx | Capital Markets
Advisors<BR>
North American Equities Desk<BR>
inspira@arxadvisory.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O ,@# 2(  A$! Q$!_\0
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M=LZA\_,1G' ->PBWMXOWBPQJ5&<A "/\\T2BX[@G<GI*I6&KVFI'; T@;8)
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;EK9,A@1DV*R@>8Q'S-N)()Y.>_6BK=% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
